138 related articles for article (PubMed ID: 30062487)
1. TA-MUC1 as detected by the fully humanized, therapeutic antibody Gatipotzumab predicts poor prognosis in cervical cancer.
Heublein S; Friese K; Kost B; Marmé F; Kuhn C; Mahner S; Dannecker C; Mayr D; Jeschke U; Vattai A
J Cancer Res Clin Oncol; 2018 Oct; 144(10):1899-1907. PubMed ID: 30062487
[TBL] [Abstract][Full Text] [Related]
2. Potential Interplay of the Gatipotuzumab Epitope TA-MUC1 and Estrogen Receptors in Ovarian Cancer.
Heublein S; Page S; Mayr D; Schmoeckel E; Trillsch F; Marmé F; Mahner S; Jeschke U; Vattai A
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30642093
[TBL] [Abstract][Full Text] [Related]
3. Immunoreactivity of the fully humanized therapeutic antibody PankoMab-GEX™ is an independent prognostic marker for breast cancer patients.
Heublein S; Mayr D; Egger M; Karsten U; Goletz S; Angele M; Gallwas J; Jeschke U; Ditsch N
J Exp Clin Cancer Res; 2015 May; 34(1):50. PubMed ID: 25986064
[TBL] [Abstract][Full Text] [Related]
4. Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study.
Ledermann JA; Zurawski B; Raspagliesi F; De Giorgi U; Arranz Arija J; Romeo Marin M; Lisyanskaya A; Póka RL; Markowska J; Cebotaru C; Casado Herraez A; Colombo N; Kutarska E; Hall M; Jacobs A; Ahrens-Fath I; Baumeister H; Zurlo A; Sehouli J
ESMO Open; 2022 Feb; 7(1):100311. PubMed ID: 34920291
[TBL] [Abstract][Full Text] [Related]
5. Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors.
Ochsenreither S; Fiedler WM; Conte GD; Macchini M; Matos I; Habel B; Ahrens-Fath I; Raspagliesi F; Lorusso D; Keilholz U; Rolling C; Kebenko M; Klinghammer KF; Saavedra O; Baumeister H; Zurlo A; Garralda E
ESMO Open; 2022 Apr; 7(2):100447. PubMed ID: 35397434
[TBL] [Abstract][Full Text] [Related]
6. EP3 receptor is a prognostic factor in TA-MUC1-negative ovarian cancer.
Czogalla B; Kuhn C; Heublein S; Schmöckel E; Mayr D; Kolben T; Trillsch F; Burges A; Mahner S; Jeschke U; Hester A
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2519-2527. PubMed ID: 31485769
[TBL] [Abstract][Full Text] [Related]
7. Staining of MUC1 in ovarian cancer tissues with PankoMab-GEX detecting the tumour-associated epitope, TA-MUC1, as compared to antibodies HMFG-1 and 115D8.
Dian D; Lenhard M; Mayr D; Heublein S; Karsten U; Goletz S; Kuhn C; Wiest I; Friese K; Weissenbacher T; Jeschke U
Histol Histopathol; 2013 Feb; 28(2):239-44. PubMed ID: 23275306
[TBL] [Abstract][Full Text] [Related]
8. TA-MUC1 epitope in non-small cell lung cancer.
Kuemmel A; Single K; Bittinger F; Faldum A; Schmidt LH; Sebastian M; Micke P; Taube C; Buhl R; Wiewrodt R
Lung Cancer; 2009 Jan; 63(1):98-105. PubMed ID: 18539357
[TBL] [Abstract][Full Text] [Related]
9. Expression of the Tumor-associated Mucin 1 Epitope Analyzed with the Humanized PankoMab-GEX™ Antibody in Malignant and Normal Tissues of the Head and Neck.
Wiest I; Alexiou C; Friese K; Betz P; Tübel J; Goletz S; Dian D; Jeschke U
Anticancer Res; 2016 Jun; 36(6):3179-84. PubMed ID: 27272845
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the anti-Thomsen-Friedenreich antibodies Nemod-TF1 and Nemod-TF2 as prognostic markers in breast cancer.
Heublein S; Egger M; Zhu J; Berger L; Mayr D; Schindlbeck C; Kuhn C; Hofmann SS; Schuetz F; Jeschke U; Ditsch N
Breast Cancer Res Treat; 2020 Feb; 179(3):643-652. PubMed ID: 31828591
[TBL] [Abstract][Full Text] [Related]
11. MUC1 promotes cervical squamous cell carcinoma through ERK phosphorylation-mediated regulation of ITGA2/ITGA3.
Zhao A; Pan Y; Gao Y; Zhi Z; Lu H; Dong B; Zhang X; Wu M; Zhu F; Zhou S; Ma S
BMC Cancer; 2024 May; 24(1):559. PubMed ID: 38702644
[TBL] [Abstract][Full Text] [Related]
12. Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity.
Lavrsen K; Madsen CB; Rasch MG; Woetmann A; Ødum N; Mandel U; Clausen H; Pedersen AE; Wandall HH
Glycoconj J; 2013 Apr; 30(3):227-36. PubMed ID: 22878593
[TBL] [Abstract][Full Text] [Related]
13. Reactivity of a humanized antibody (hPankoMab) towards a tumor-related MUC1 epitope (TA-MUC1) with various human carcinomas.
Fan XN; Karsten U; Goletz S; Cao Y
Pathol Res Pract; 2010 Aug; 206(8):585-9. PubMed ID: 20400237
[TBL] [Abstract][Full Text] [Related]
14. Aldehyde Dehydrogenase 1 Expression Predicts Chemoresistance and Poor Clinical Outcomes in Patients with Locally Advanced Cervical Cancer Treated with Neoadjuvant Chemotherapy Prior to Radical Hysterectomy.
Xie Q; Liang J; Rao Q; Xie X; Li R; Liu Y; Zhou H; Han J; Yao T; Lin Z
Ann Surg Oncol; 2016 Jan; 23(1):163-70. PubMed ID: 25916979
[TBL] [Abstract][Full Text] [Related]
15. Clinical implication of voltage-dependent anion channel 1 in uterine cervical cancer and its action on cervical cancer cells.
Wu CH; Lin YW; Wu TF; Ko JL; Wang PH
Oncotarget; 2016 Jan; 7(4):4210-25. PubMed ID: 26716410
[TBL] [Abstract][Full Text] [Related]
16. Expression of mucin-associated carbohydrate core antigens in esophageal squamous cell carcinomas.
Flucke U; Zirbes TK; Schröder W; Mönig SP; Koch V; Schmitz K; Thiele J; Dienes HP; Hölscher AH; Baldus SE
Anticancer Res; 2001; 21(3C):2189-93. PubMed ID: 11501845
[TBL] [Abstract][Full Text] [Related]
17. Expression of Twist enhances risk of poor oncologic outcome in patients with stage Ib to II cervical carcinoma with lymphovascular space involvement.
Kajiyama H; Shibata K; Umezu T; Mizuno M; Suzuki S; Yamamoto E; Fujiwara S; Kikkawa F
Hum Pathol; 2013 Feb; 44(2):181-8. PubMed ID: 22974479
[TBL] [Abstract][Full Text] [Related]
18. Expression of mucin antigens (MUC1 and MUC16) as a prognostic factor for mucinous adenocarcinoma of the uterine cervix.
Togami S; Nomoto M; Higashi M; Goto M; Yonezawa S; Tsuji T; Batra SK; Douchi T
J Obstet Gynaecol Res; 2010 Jun; 36(3):588-97. PubMed ID: 20598042
[TBL] [Abstract][Full Text] [Related]
19. Significant effects of lymph and blood vascular invasion on the prognosis of early-stage cervical squamous cell carcinoma.
Zhang Y; Yan M; He J; Sun J; Sun X
J Obstet Gynaecol Res; 2010 Oct; 36(5):1015-22. PubMed ID: 20846259
[TBL] [Abstract][Full Text] [Related]
20. NR2F6 Expression Correlates with Pelvic Lymph Node Metastasis and Poor Prognosis in Early-Stage Cervical Cancer.
Niu C; Sun X; Zhang W; Li H; Xu L; Li J; Xu B; Zhang Y
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27775588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
